Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | Backorder |
Description | Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production, thereby reducing urinary oxalate excretion. This compound shows promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran sodium is utilized in the study of Primary Hyperoxaluria Type 1 (PH1). It functions by silencing the gene responsible for glycolate oxidase production, subsequently reducing glycolate oxidase levels. This inhibition blocks oxalate synthesis, the harmful metabolite linked to PH1's clinical symptoms[1]. |
In vivo | Lumasiran sodium is a liver-targeted therapeutic agent administered subcutaneously, functioning through RNA interference (RNAi) [2]. |
Cas No. | 1834612-06-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.